H.C. Wainwright Reiterates Buy Rating on Coya Therapeutics (COYA)

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $18.00 price target on Coya Therapeutics (NASDAQ: COYA).

The analyst commented: "Late last month, Coya Therapeutics announced that Health Canada has accepted, without objection, the Clinical Trial Application (CTA) for COYA 302 to treat amyotrophic lateral sclerosis (ALS). Health Canada's CTA acceptance allows for activation of clinical sites in Canada, enhancing patient recruitment alongside the U.S. clinical sites. We reiterate our Buy rating and 12-month target of $18."

For an analyst ratings summary and ratings history on Coya Therapeutics click here. For more ratings news on Coya Therapeutics click here.

Shares of Coya Therapeutics closed at $5.65 yesterday.

You May Also Be Interested In

• Ackman adds Netflix, Visa and Mastercard in portfolio revamp
• SPAR Group (SGRP) Reports Q2 EPS of $0.04
• GE Vernova and Blue Energy advance Texas gas-nuclear plant plan